Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HEMP $.2's next leg $.07
$HEMP $.2's next leg $.07
$CIIX Short Term Pinch #STP
$CIIX Short Term Pinch #STP
Trump officially legalizes industrial hemp https://thehill.com/homenews/administration/422356-trump-officially-legalizes-industrial-hemp
Trump officially legalizes industrial hemp https://thehill.com/homenews/administration/422356-trump-officially-legalizes-industrial-hemp
$CIIX The market of CBD
Cannabidiol is one of the fastest growing market categories in the U.S. hemp and legal marijuana industries with a compound annual growth rate of 59%. In 2015, the CBD industry grew from a nearly invisible market a few years ago to $202 million in consumer sales, and it is further expected to grow to $2.1 billion in consumer sales by 2020 with $450 million of those sales coming from hemp based sources.
http://chineseinvestors.com/opportunities-in-cbd/
$CIIX The market of CBD
Cannabidiol is one of the fastest growing market categories in the U.S. hemp and legal marijuana industries with a compound annual growth rate of 59%. In 2015, the CBD industry grew from a nearly invisible market a few years ago to $202 million in consumer sales, and it is further expected to grow to $2.1 billion in consumer sales by 2020 with $450 million of those sales coming from hemp based sources.
http://chineseinvestors.com/opportunities-in-cbd/
* * $CIIX $.52 +0.05 (+10.64%) on a TEAR $$$$$
* * $CIIX $.52 +0.05 (+10.64%) on a TEAR $$$$$
5 Marijuana Stocks Ready To Explode $CGC $CIIX $APHA $INSY $GWPH https://www.marketwatch.com/press-release/5-marijuana-stocks-ready-to-explode-2018-08-14
5 Marijuana Stocks Ready To Explode $CGC $CIIX $APHA $INSY $GWPH https://www.marketwatch.com/press-release/5-marijuana-stocks-ready-to-explode-2018-08-14
$HEMP Hemp, Inc. Provides CBS Behind-The-Scenes Access to the Largest Hemp Processing Mill in the Western Hemisphere https://globenewswire.com/news-release/2018/04/09/1466793/0/en/Hemp-Inc-Provides-CBS-Behind-The-Scenes-Access-to-the-Largest-Hemp-Processing-Mill-in-the-Western-Hemisphere.html
$INSY Epinephrine
As a needle-free delivery method, INSYS’ epinephrine nasal spray represents a potential alternative to intramuscular injection. As reported in June 2018, the proof-of-concept study for the company’s epinephrine nasal spray product candidate showed that the drug as formulated was readily absorbed through the nasal mucosa. Subsequently, the FDA granted Fast Track designation for this investigational product in August of 2018 and provided specific guidance for clinical development and filing requirements at the end-of-Phase 2 meeting in August.
Given clinical and regulatory progress to date, INSYS believes the epinephrine NDA remains on track for filing during the fourth quarter of 2019, pending successful completion of a confirmatory PK study and no additional clinical studies requested by the FDA. The confirmatory PK study will follow completion of the now fully enrolled 48-patient dose-finding study that is expected to report results in March. Considering the Fast Track designation, INSYS plans to meet again with the FDA early in the second quarter to confirm the design of the subsequent clinical development program.
Also of note, data from the product candidate’s clinical development program will be presented at the American Academy of Allergy, Asthma and Immunology 2019 annual meeting in late February 2019. The abstract, titled “A Phase 1, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults with Seasonal Allergies,” has been accepted as a poster presentation.
$INSY Cannabidiol
All three trials with CBD oral solution are enrolling patients, including a Phase 2 study of childhood absence epilepsy, a Phase 3 study of infantile spasms, and a Phase 2 study of Prader-Willi syndrome.
The company expects to show initial results from the Phase 2 trial in childhood absence epilepsy late in the first quarter 2019 as the company continues to enroll patients.
Results of the long-term safety study of CBD in refractory pediatric epilepsy were reported on Dec. 3 at the American Epilepsy Society 2018 annual meeting and showed that the company’s proprietary formulation of the drug was generally well-tolerated, even at high doses, through 48 weeks of follow up.
The company is continuing to enroll patients in a Phase 2 study of Prader-Willi Syndrome across seven clinical sites with a plan to add additional sites in 2019. The company expects full results of this study in the second half of 2019.
Enrollment in the company’s Phase 3 study of infantile spasms has occurred at a slower pace than anticipated, and the company will provide an update once it has better visibility into enrollment.
Additionally, the company is committed to supporting three studies planned by the University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) for initiation in 2019. The investigational new drug (IND) for CMCR’s autism study has been opened, and the INDs for the studies of early psychosis and anxiety in anorexia nervosa are expected to be opened in the first half of 2019—in the first and second quarters, respectively. Meanwhile, the company’s support for a study of CBD in cocaine dependence continues at the University of Montreal.
Lastly, alternative oral-dose formulations of CBD are in early development. With results from nonclinical studies expected in the first quarter, the next phase of development, including clinical trials targeting additional chronic indications, is scheduled to commence in the latter part of 2019.
$INSY Cannabidiol
All three trials with CBD oral solution are enrolling patients, including a Phase 2 study of childhood absence epilepsy, a Phase 3 study of infantile spasms, and a Phase 2 study of Prader-Willi syndrome.
The company expects to show initial results from the Phase 2 trial in childhood absence epilepsy late in the first quarter 2019 as the company continues to enroll patients.
Results of the long-term safety study of CBD in refractory pediatric epilepsy were reported on Dec. 3 at the American Epilepsy Society 2018 annual meeting and showed that the company’s proprietary formulation of the drug was generally well-tolerated, even at high doses, through 48 weeks of follow up.
The company is continuing to enroll patients in a Phase 2 study of Prader-Willi Syndrome across seven clinical sites with a plan to add additional sites in 2019. The company expects full results of this study in the second half of 2019.
Enrollment in the company’s Phase 3 study of infantile spasms has occurred at a slower pace than anticipated, and the company will provide an update once it has better visibility into enrollment.
Additionally, the company is committed to supporting three studies planned by the University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) for initiation in 2019. The investigational new drug (IND) for CMCR’s autism study has been opened, and the INDs for the studies of early psychosis and anxiety in anorexia nervosa are expected to be opened in the first half of 2019—in the first and second quarters, respectively. Meanwhile, the company’s support for a study of CBD in cocaine dependence continues at the University of Montreal.
Lastly, alternative oral-dose formulations of CBD are in early development. With results from nonclinical studies expected in the first quarter, the next phase of development, including clinical trials targeting additional chronic indications, is scheduled to commence in the latter part of 2019.
$CIIX NO BRAINER!
$CIIX NO BRAINER!
CBD $CIIX GOT FEW CHEAPIES..NOT ENOUGH THOUGH
Hemp is now LEGAL $HEMP on watch
$CIIX Powering up, coming. Patience!!!! CIIX
$CIIX Powering up, coming. Patience!!!! CIIX
$CIIX #hemp #cannabis
$CIIX #hemp #cannabis
Loading Zone CBD $CIIX #ELLIOTWAVE
Loading Zone CBD $CIIX #ELLIOTWAVE
loading zone $HEMP
$INSY "SYNDROS® is a cannabinoid medicine used in adults to treat:
Loss of appetite (anorexia) in people with AIDS (Acquired Immune Deficiency Syndrome) who have lost weight
Nausea and vomiting caused by anti-cancer medicine (chemotherapy) in people whose nausea and vomiting have not improved with usual anti-nausea and vomiting medicines
SYNDROS® is the first and only FDA-approved liquid dronabinol, which allows for fast absorption, flexible dosing and a potential solution for patients who may prefer a liquid medication."
https://www.insysrx.com/products/approved
$INSY "SYNDROS® is a cannabinoid medicine used in adults to treat:
Loss of appetite (anorexia) in people with AIDS (Acquired Immune Deficiency Syndrome) who have lost weight
Nausea and vomiting caused by anti-cancer medicine (chemotherapy) in people whose nausea and vomiting have not improved with usual anti-nausea and vomiting medicines
SYNDROS® is the first and only FDA-approved liquid dronabinol, which allows for fast absorption, flexible dosing and a potential solution for patients who may prefer a liquid medication."
https://www.insysrx.com/products/approved
Hemp, Inc. $HEMP & Creation of Proprietary Industrial Hemp Strains as U.S. Senate Supports Cannabis Seed Bank https://www.gurufocus.com/news/689417/hemp-inc-announces-creation-of-proprietary-industrial-hemp-strains-as-us-senate-supports-cannabis-seed-bank
Hemp, Inc. $HEMP & Creation of Proprietary Industrial Hemp Strains as U.S. Senate Supports Cannabis Seed Bank https://www.gurufocus.com/news/689417/hemp-inc-announces-creation-of-proprietary-industrial-hemp-strains-as-us-senate-supports-cannabis-seed-bank
============ CIIX Launches Hemp Wine =================
$CIIX Upcoming Launch of CBD Hemp Wine https://smallcapvoice.com/blog/chineseinvestors-com-inc-announces-upcoming-launch-of-cbd-hemp-wine/
============ CIIX Launches Hemp Wine =================
$CIIX Upcoming Launch of CBD Hemp Wine https://smallcapvoice.com/blog/chineseinvestors-com-inc-announces-upcoming-launch-of-cbd-hemp-wine/
$CIIX CBD oil is considered to have a broad range of medical benefits, and it is non-psychoactive with low-THC and high-CBD content. CBD has shown varying degrees of efficacy in treating epilepsy, Alzheimer’s disease, cirrhosis, pain, anxiety and stress. Given the wide ranging practice of holistic-based Eastern medicine, acceptance and use of CBD oils is not only a natural adjunct, but also an enormous potential revenue generator for ChineseInvestors.com, which suggests that online sales and future retail outlets could easily exceed expectations. All told, ChineseInvestors.com presents an interesting opportunity to profit from the meteoric rise of the medical marijuana market as it relates to a global population of more than two billion Chinese consumers. http://blog.qualitystocks.net/chineseinvestors-com-inc-ciix/chineseinvestors-com-inc-ciix-aims-to-excel-in-cbd-markets/amp/
$CIIX CBD oil is considered to have a broad range of medical benefits, and it is non-psychoactive with low-THC and high-CBD content. CBD has shown varying degrees of efficacy in treating epilepsy, Alzheimer’s disease, cirrhosis, pain, anxiety and stress. Given the wide ranging practice of holistic-based Eastern medicine, acceptance and use of CBD oils is not only a natural adjunct, but also an enormous potential revenue generator for ChineseInvestors.com, which suggests that online sales and future retail outlets could easily exceed expectations. All told, ChineseInvestors.com presents an interesting opportunity to profit from the meteoric rise of the medical marijuana market as it relates to a global population of more than two billion Chinese consumers. http://blog.qualitystocks.net/chineseinvestors-com-inc-ciix/chineseinvestors-com-inc-ciix-aims-to-excel-in-cbd-markets/amp/
CIIX CBD Cannabis Medical Marijuana $CIIX Significant Revenue Growth in FY2018 Financial Results https://www.cannabisnewswire.com/cannabisnewsbreaks/cannabisnewsbreaks-chineseinvestors-com-inc-ciix-records-significant-revenue-growth-in-fy2018-financial-results/
CIIX CBD Cannabis Medical Marijuana $CIIX Significant Revenue Growth in FY2018 Financial Results https://www.cannabisnewswire.com/cannabisnewsbreaks/cannabisnewsbreaks-chineseinvestors-com-inc-ciix-records-significant-revenue-growth-in-fy2018-financial-results/
5G Wireless: A Dangerous ‘Experiment on Humanity’
5G Wireless: A Dangerous ‘Experiment on Humanity’